Adelina Ghilencea

Dr. Adelina Ghilencea


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Daniel Octavian CostacheDaniel Octavian Costache
Daniel Octavian Costache
OFOana Feroiu
Oana Feroiu
AGAdelina Ghilencea
Adelina Ghilencea
MGMihaela Georgescu
Mihaela Georgescu
Ana CaruntuAna Caruntu
Ana Caruntu
RCRaluca Simona Costache
Raluca Simona Costache
The systemic inflammatory syndrome concept is one of the foundations that stand at the basis of revolutionary modern and future therapies, based on the in-depth understanding of the delicate mechanisms that govern the collaboration between the systems and organs of the human body and, at the same time, the fine balance that ensures a reproach-free operation. An interesting concept that we propose is that of the environment-inadequacy status, a concept that non-specifically incorporates all the situations of the organism’s response disorders in the face of imprecisely defined situations of the environment. The correlation between these two concepts will define the future of modern medicine, along with the gene-adjustment mechanisms. Psoriasis is a clear example of an inadequate body response as a result of exposure to as of yet undefined triggers with an excessive systemic inflammatory reaction and hitherto insufficiently controllable. Modern biological therapies, such as TNF-α, IL-12 family, and IL-17 inhibitors, are intended to profoundly reshape the cytokine configuration of patients with inflammatory diseases such as psoriasis, with tremendous success in disease control. Yet, because of the important roles of cytokines in cancer promotion and control, concern was raised about the fact that the use of biologicals may alter immune surveillance and promote cancer progression. Both theoretical and practical data nevertheless showed that the treatment-induced control of cytokines may be beneficial for reducing the inflammatory milieu that promotes cancer and such have a beneficial role in maintaining health. We briefly present the intricate roles of those cytokine families on cancer control, with some debates on if their inhibition might or might not promote additional tumoral development.

13 July 2026 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
AGAdelina Ghilencea
Adelina Ghilencea
Daniel Octavian CostacheDaniel Octavian Costache
Daniel Octavian Costache
Constantin CaruntuConstantin Caruntu
Constantin Caruntu
MMMaria Moga
Maria Moga
RCRaluca Simona Costache
Raluca Simona Costache
Introduction. Psoriasis is a chronic inflammatory disease histologically characterized by epidermal hyperproliferation, altered keratinocyte differentiation and dermal vascular remodeling. Although the diagnosis is mainly clinical, non-invasive imaging methods, such as high-frequency skin ultrasound, allow an objective assessment of skin changes and disease activity. Material and Methods. We conducted a pilot, observational, cross-sectional and comparative study, conducted within the Dermatovenerology Department of the Central Military Emergency Hospital “Dr. Carol Davila”, Bucharest, which included 40 patients diagnosed with psoriasis vulgaris, of whom 22 received conventional systemic treatment (methotrexate 15 mg/week), and 18 received biological therapy. For each patient, a representative, clinically active and recently appeared psoriatic plaque was evaluated with ultrasound, and the thickness of the epidermis, the thickness of the dermis, the thickness of the hypoechoic subepidermal band (SLEB) and the Doppler signal were analyzed. Statistical analysis was performed using SPSS v26. Results. Patients under biologic therapy had significantly lower ultrasound parameters compared to those under conventional systemic therapy, especially regarding epidermis thickness, hypoechoic subepidermal band thickness and Doppler signal. The PASI score was significantly higher in the conventionally treated group. Also, significant positive correlations were found between the PASI score and the hypoechoic subepidermal band thickness and the Doppler signal, Conclusions. Ultrasound parameters represent useful objective markers in the evaluation of psoriasis, reflecting disease activity. Patients under biologic therapy presented, at the time of evaluation, imaging parameters suggestive of reduced skin inflammation compared to those treated conventionally.

23 September 2026 in Romanian Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
AGAdelina Ghilencea
Adelina Ghilencea
Daniel Octavian CostacheDaniel Octavian Costache
Daniel Octavian Costache
Constantin CaruntuConstantin Caruntu
Constantin Caruntu
Cristian ScheauCristian Scheau
Cristian Scheau
ISIlinca Savulescu-Fiedler
Ilinca Savulescu-Fiedler
RCRaluca Simona Costache
Raluca Simona Costache
Introduction: Psoriasis is a chronic systemic inflammatory disease, frequently associated with metabolic comorbidities that may influence therapeutic outcomes. Real-world evidence on the effectiveness of biologic therapy in this complex clinical context remains limited. Objectives: To assess the prevalence of comorbidities in patients with psoriasis receiving biologic therapy and to identify factors associated with treatment response. Methods: A retrospective observational study including 121 patients with chronic plaque psoriasis. Demographic data, comorbidities, biologic treatment class, and PASI/DLQI evolution at baseline and at standardized 6 and 12 months assessments was analyzed, together with the latest available clinical assessment recorded in 2025 after variable treatment durations. Results: Comorbidities were present in 84.3% of patients, most frequently hepatic steatosis (73.6%), obesity (45.5%), hypertension (41.3%), and diabetes (19%). A significant improvement in PASI and DLQI scores was observed at all follow-up points (p < 0.001). Complete skin clearance (PASI 100) was achieved by 18.1% of the patients at 6 months and by 44.6% at 12 months. In multivariable logistic regression analysis, lower PASI scores at six months were independently associated with a higher likelihood of achieving PASI 100 at one year. Conclusions: Biologic therapy was associated with marked clinical and quality-of-life improvement. Although metabolic comorbidities were highly prevalent, no significant association between metabolic comorbidities and PASI 100 response at one year was identified in the analyses performed.